Research progress of lenalidomide in the treatment of lymphoma：reports from the 57th American Society of Hematology annual meeting

VernacularTitle:来那度胺在淋巴瘤治疗中的研究进展：第57届美国血液学会年会报道
Author: Jun XIA ; Wei XU ; Jianyong LI
Publication Type:Journal Article
Keywords: Lymphoma; Lenalidomide; Treatment progress; American Society of Hematology annual meeting
From: Journal of Leukemia & Lymphoma 2016;25(3):153-156
CountryChina
Language:Chinese
Abstract: Lenalidomide is an oral immunomodulator with multiple functions including immune regulation, anti-tumor, and regulation of tumor microenvironment. Since the United States Food and Drug Administration (FDA) approved lenalidomide for the treatment of mantle cell lymphoma, recent studies have indicated that lenalidomide monotherapy or lenalidomide combinations in other types of lymphoma also has broad prospects. The treatment progress of lenalidomide in lymphoma will be summarized in this paper based on the new reports in the 57th American Society of Hematology (ASH) annual meeting.